Table 1 Summary of clinical and neuropathological features of control (healthy), C9-ALS and sporadic (non-C9) ALS patient post-mortem brain tissues used in this study
From: RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3
Case ID | Gender | Race | Age at death | Age at onset | Duration of disease after diagnosis (years) | Primary onset | Clinical diagnosis | Primary neuropathology diagnosis | Additional neuropathology diagnoses |
|---|---|---|---|---|---|---|---|---|---|
CW01-97 | F | W | 57 | N/A | N/A | N/A | Normal* | Metastatic lung carcinoma | 1. Primary age-related Tauopathy; 2. Mild acute ischemic injury, hippocampus |
CW01-98 | M | W | 76 | N/A | N/A | N/A | Normal* | Alzheimer’s disease neuropathologic change, intermediate level | Remote frontal lobe infarct |
CW99-100 | M | W | 54 | N/A | N/A | N/A | Normal* | No pathologic changes | Â |
CW03-130 | M | W | Â | Not available | Not available | Not available | ALS | ALS (C9orf72 pattern) | Â |
CW07-94 | F | W | 63 | 59 | 4 | Hand weakness | ALS | ALS (C9orf72 pattern) | Alzheimer’s disease neuropathologic change, low level |
CW07-96 | M | W | 67 | Not available | Not available | Not available | ALS | ALS (C9orf72 pattern) | Alzheimer’s disease neuropathologic change, low level |
CW13-97 | F | W | 62 | 58 | 4 | Leg weakness | ALS | ALS and FTLD-TDP (C9orf72 pattern) | Alzheimer’s disease neuropathologic change, low level |
CW98-96 | M | W | 43 | 42 | 1 | Not available | ALS | ALS (C9orf72 pattern) | Â |
CW98-97 | F | W | 51 | 49 | 2 | Not available | ALS | ALS (C9orf72 pattern) | Â |
CW12-96 |  | Unknown | 59 | 57 | 1.7 | Leg weakness | ALS | ALS | Alzheimer’s disease neuropathologic change, low level |
CW15-99 | F | W | 51 | 46 | 5 | Leg weakness | ALS | ALS | Alzheimer’s disease neuropathologic change, low level |
CW12-97 | M | W | 58 | 58 | 0.6 | Dysarthria | ALS | ALS | Primary age-related tauopathy |